Introduction

OMB# 0925-0046-21 Exp. Date: 2/28/2013

The National Cancer Institute's Cancer Therapy Evaluation Program (CTEP) and the [INSERT COOPERATIVE GROUP NAME] would like your opinions about a new NCI clinical trial for [INSERT CANCER TYPE] cancer not yet open. This trial will be called the [INSERT TRIAL NAME] trial ([INSERT NCI TRIAL CODE]) and will require patients with [INSERT ONE LINE DESCRIPTION OF PATIENT ELIGIBILITY].

We are soliciting feedback from clinical oncology researchers to learn any potential issues with opening and accruing to this trial.

NCI has developed a brief online survey to quickly and easily gather your comments anonymously.

The **PDF** attachment to your email invitation provides an overview of the [INSERT TRIAL NAME] trial's concept. After reviewing this brief document we ask that you take 5 minutes to answer this short survey.

Your comments will help us plan in advance for any concerns about the [INSERT TRIAL NAME] trial identified from this survey. We **thank you** for your assistance!

To continue and begin the survey, click the "Next" button below.

Next -->

If you experience any technical difficulties, please contact the survey administrator at User-Centered Design at survey@user-centereddesign.com

National Cancer Institute

U.S. National Institutes of Health | www.cancer.gov

Privacy Statement and Consent

Your participation in this survey is completely voluntary. Please be assured that your participation in the survey is anonymous and your responses will never be linked or associated with you.

You may skip any questions that you prefer not to answer. You are also free to stop participating at any point during the survey and have your responses deleted by clicking the "Opt out of survey" box at the bottom of each survey page.

This brief survey should only require approximately 5 minutes of your time.

Please click the "Next" button if you consent to taking this survey.

Opt out of survey

Next -->

Public reporting burden for this collection of information is estimated to average 5 minutes per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing the collection of information. An agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a currently valid OMB control number. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden, to: NIH, Project Clearance Branch, 6705 Rockledge Drive, MSC 7974, Bethesda, MD 208927974, ATTN: PRA (0925-0046-21). Do not return the completed form to this address.

If you experience any technical difficulties, please contact the survey administrator at User-Centered Design at survey@user-centereddesign.com

Opt out of survey

I have reviewed the concept sheet and am ready to begin -->

If you experience any technical difficulties, please contact the survey administrator at User-Centered Design at survey@user-centereddesign.com

National Cancer Institute	U.S. National Institutes of Health www.cancer.gov
Please reply to all questions from the perspective of <u>your</u> site.	
1. Please indicate which best describes your site:	
 My practice is located within an academic medical center 	
 My practice is located within an NCI designated cancer center 	
My practice is located within a community hospital	
I/We are a free-standing private practice Other:	
Other.	
1a. What best describes the size of your community hospital compare	ed to others?
○ We are a small-size community hospital (less than 100 beds)	
 We are a mid-size community hospital (between 100-250 beds 	s)
 We are a large-size community hospital (more than 250 beds) 	
What type of oncology best describes your expertise?	
Medical oncology	
 Surgical oncology 	
 Radiation oncology 	
 Gynecologic oncology 	
O Pediatric oncology	
Other:	
Opt out of survey	Save and Continue>
If you experience any technical difficulties, please contact at User-Centered Design at <u>survey@user-cente</u>	

National (Cancer Ins	titute		U.S. National Institut	les of Health www.cancer.gov
3. Which specialty at your institution would initially see most of the patients potentially eligible for the [INSERT TRIAL NAME] trial (i.e., [INSERT BRIEF PATIENT ELIGIBILITY DESCRIPTION])?					
Medical oncolo	gy				
 Surgical oncole 					
Radiation oncoGynecologic or					
Pediatric oncol	0,				
Other (please s					
scientifically interesting	ng it is to you. SEARCH QU	JESTION #1 FI	ROM TRIAL D	ESCRIPTION SHEET Very interesting	
DOO! IINGEDT DE	OF A DOLL OF	IECTION #0 E	DOM TOWN D	ECODIDITION CLIEFT	IE ADDI IOADI E10
How scientifically i				ESCRIPTION SHEET ?	, IF APPLICABLEJ?
,	g		,		
Not at all interesting				Very interesting	
0	\circ	\circ		0	
Opt out of survey					Save and Continue>
				contact the survey administra r-centereddesign.com	tor

Nation	nal Cancer Ins	titute	U.S. National Insti	tutes of Health www.cancer.gov
	e [INSERT TRIAL N In treatment of [INS			do you believe the findings
Limited impact			High impact	
	\bigcirc	\bigcirc		
Please elabo	orate on your answ	er:		
Opt out of survey			ontact the survey administ centereddesign.com	Save and Continue>

N. RETEROLISM					
National	Cancer Insti	tute		U.S. National Institut	tes of Health www.cancer.gov
6. Given what you re NAME] trial at your si		t sheet summar	y, how interest	ed are you in openinç	g the [INSERT TRIAL
Not at all interested				Very interested	
0				0	
6a. What are the top reasons why you are not that interested in opening the [INSERT TRIAL NAME] trial? [Select up to 3.] Not scientifically interesting enough Does not match our patient population Limited interest by oncologist(s) here Too many competing trials for this cancer Too great of a burden on patients (e.g., logistics, cost) Too difficult to conduct the study (e.g., burden on staff, coordination required, equipment needed) Financial cost to our site would be too great (e.g., non-reimbursable expenses) Too difficult to accrue patients Concerns about drug availability Other:					
to 3.] Scientifically in Fills unmet nee High level of ir Few competing Limited burder Ease of doing Limited non-re Availability of s Ease in accruit	nteresting researced for our current nterest by oncolor g trials for this can n on patient (e.g., the study (e.g., li imbursable expe	ch question(s) t patient popula gist(s) in the pra ncer , logistics, cost) mited burden o	tion actice	ening the [INSERT TR	
Opt out of survey					Save and Continue>
		ice any technical dif Iser-Centered Design		ntact the survey administrat entereddesign.com	tor

	猫 National	Cancer Ins	stitute		U.S. I	National Institute	es of Health wv	ww.cancer.gov
7. F	low difficult do y	ou believe the	[INSERT TRIAL	. NAME] trial wi	ll be to o	oen at your s	ite?	
	Not at all difficult				Very diff	icult		
	\circ	\circ	\circ	\circ	\circ			
	the [INSERT TR	RIAL NAME] tri	nts listed below, al at your site. ment make it to your site?			Not make it difficult to open/ run the trial	Make it somewhat difficult to open/run the trial	Make it very difficult to open/run the trial
	[INSERT REQU	IREMENT #1	FROM DESCRI	PTION SHEET]	0	0	
ľ	[INSERT REQU	IREMENT #2	FROM DESCRI	PTION SHEET]	0	0	0
ĺ	[INSERT REQU	IREMENT #3	FROM DESCRI	PTION SHEET]	0	0	0
	[INSERT THR SHEET]	ROUGH REQU	IIREMENT #N F	ROM DESCRI	PTION	0	0	0
Opt	out of survey		rience any technical d User-Centered Desig					and Continue>

National Cancer Institute	U.S. National Institutes of Health www.cancer.gov
9. How often do you see a patient who may be eligible for the [INSERPATIENT ELIGIBILITY DESCRIPTION])?	RT TRIAL NAME] trial (i.e., [INSERT BRIEF
10. If your site were to open this trial, about how many patients do yo [INSERT TRIAL NAME] trial in a year? [Number of patients - integers only)	ou believe your site could accrue to the
Opt out of survey	Save and Continue>
If you experience any technical difficulties, please contar at User-Centered Design at <u>survey@user-cent</u>	

National Cancer Institut

U.S. National Institutes of Health | www.cancer.gov

11. For each of the items below, please tell us whether or not you think it will make it difficult to $\underline{accrue\ patients}$ to the [INSERT TRIAL NAME] trial.

How difficult will this issue make it to accrue patients to this trial?	Not make it difficult to accrue patients to the trial	Make it somewhat difficult to accrue patients to the trial	Make it very difficult to accrue patients to the trial
Inclusion/exclusion criteria of the trial			
Getting patients referred to the trial			
Patients declining to enroll (e.g., unwilling to randomize, prefer one study arm)	0	0	0
Burden on patient to participate in the trial (e.g., logistics, time)			
Explaining the trial's details to a patient, including consenting			
Cost to the patient (e.g., insurance, reimbursement)			

Please	tell us in the	box below	if there are o	ther reasons	, not listed abo	ve, that migh	t make this tria	d difficult to
accrue	patients at y	our site:						

- 1		
- 1		
- 1		
- 1		
- 1		
- 1		
- 1		
L		

Opt out of survey

Save and Continue -->

If you experience any technical difficulties, please contact the survey administrator at User-Centered Design at survey@user-centereddesign.com

	National Cancer Institute u.s. National Institute	es of Health www.cancer.gov				
	12. How many similar trials are open at your site that would compete for the same patient population as the [INSERT TRIAL NAME] trial?					
	Number of similar trials open at your site from each sponsor (Integers only)	Which sponsor group most competes for the same patient population as this new trial?				
	# competing trials that are sponsored by NCI (including cooperative group trials	s) 🔾				
	# competing trials that are sponsored by pharmaceutical/biotech industry	0				
cer	# competing trials that are investigator initiated trials from academic medical inters	0				
Opt ou	t of survey	Save and Continue>				
	If you experience any technical difficulties, please contact the survey administrat at User-Centered Design at survey@user-centereddesign.com	or				



National Cancer Institute	U.S. National Institutes of Health www.cancer.gov				
Survey Complete					
Thank you for completing	ng this survey!				
Your answers have been submitted anonymously.					
We appreciate your feedback regarding the [INSERT TRIAL NAME] trial. Your comments will help ensure that we plan in advance for any concerns identified.					
If you would like a summary of the findings after the 61164thfirlab@mai	•				
You may now close the	nis window.				
If you experience any technical difficulties, pleas at User-Centered Design at <u>survey@u</u>					